Overview

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Status:
RECRUITING

Trial end date:
2030-07-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Phase:

PHASE3

Details

Lead Sponsor:

Merus N.V.

Treatments:

pembrolizumab